Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.
Info & Links
CEO
Brett P. Monia
Headquarters
2855 GAZELLE COURT CARLSBAD, CA 92010, UNITED STATES
Ionis Pharmaceuticals, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
4.70B
Enterprise Value
5.70B
Enterprise Value/EBITDA(ttm)
-11.78
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
7.37
Price to Book(mrq)
8.77
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
98.47%
Operating Margin(ttm)
-64.25%
Profit Margin(ttm)
-74.99%
Return on Equity(ttm)
-100.05%
Return on Invested Capital(ttm)
-26.88%
Return on Assets(ttm)
-15.70%
Income Statement
Revenue(ttm)
705.14M
Revenue Per Share(ttm)
4.44
Gross Profit(ttm)
693.92M
EBITDA(ttm)3
-484.13M
Net Income Available to Common(ttm)
-453.90M
Diluted EPS(ttm)
-3.04
Share Statistics
Beta (5Y Monthly)
0.34
52-Week Change
-29.35%
S&P 500 52-Week Change
8.64%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
158.96M
Dividend Yield
0.00%
Float4
153.62M
% Held by Insiders
2.71%
% Held by Institutions
93.86%
Balance Sheet
Total Cash(mrq)
2.30B
Total Cash Per Share(mrq)
14.45
Total Debt(mrq)
1.25B
Total Debt/Equity(mrq)
211.69%
Current Ratio(mrq)
8.47%
Quick Ratio(mrq)
8.82%
Book Value Per Share(mrq)
3.73
Cash Flow
Operating Cash Flow Per Share(ytd)
-3.35
Free Cash Flow(ytd)
-546.23M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.